Patients with prostate cancer and diabetes have lower PSA and testosterone levels and higher serum FBS, HbA1c, insulin, and IGF-1 levels, along with a deranged lipid profile, leading to observed greater cancer grade and high risk in men with diabetes. This evidence concerns the gene INS and prostate carcinoma.